AP [3/29] | The FDA has approved selling naloxone without a prescription, the first opioid treatment drug to be sold over the counter. It’s a move that some advocates have long sought as a way to improve access to a life-saving drug, though the exact impact will not be clear immediately. Cont.
DEA [3/22] | In a public safety alert, the DEA said it observed a sharp increase in the trafficking of fentanyl mixed with xylazine, a sedative also known as “Tranq” that has been approved by the Food
U.S. Senate [3/28] | Several senators are introducing the Combating Illicit Xylazine Act, bipartisan, bicameral legislation to crack down on and schedule the highly dangerous sedative causing fatal ov
JAMA [3/28] | More than 7% of urine samples collected in a recent cross-sectional study [...] showed evidence of buprenorphine “spiking”—the intentional addition of buprenorphine tablet or residue dir